Sanofi's Lemtrada reduces relapses compared with Merck's Rebif in RRMS
This article was originally published in Scrip
Executive Summary
Ahead of filing for US and EU approval of Lemtrada (alemtuzumab), Sanofi and its subsidiary, Genzyme, highlighted new results from the CARE-MS I trial, showing that its investigational drug significantly reduces relapses compared with Rebif (Merck’s high dose subcutaneous interferon beta-1a) in patients with relapsing-remitting multiple sclerosis (RRMS).